²é¿´: 8281  |  »Ø¸´: 290
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

zhwenxing

ľ³æ (ÖøÃûдÊÖ)


[×ÊÔ´] ¡ø¡ø¡ø»¹ÊÇÖØ°õ³ö»÷£¡¡ª¡ªCellÔÓÖ¾ÆÀ³öµÄ10ƪÎÄÕ£¡È«²¿È«²Êpdf£¡

ÇëÄú¿´Ò»ÑÛ£º

1¡¢Ê×ÏÈÎÒ»¹ÊǼá³ÖÃâ·ÑÌṩÏÂÔØ£¬ÎªÁ˺ö࿴²»µ½CELLÎÄÕµijæÓÑÃÇ£¡
2¡¢ÉúÎïÉúÃü¿ÆÑ§ÁìÓòµÄ³æÓÑ£¬¿´ÕâÖÖÅ£Îij¤¼ûʶ£¡


ÎÞÂÛÄú¸ø²»¸øºÃÆÀ£¬Ö»Òª¶ÔÄúÓаïÖúÁ˾ÍÊǶÔ×ÊÔ´µÄÁ¼ºÃÀûÓá£

¸Ðл³æÓÑÖ§³Ö£¡

ÒÔºóÈÔÈ»¼á³Ö·¢Ãâ·ÑµÄ×ÊÔ´Ìû¡£ÍûÖÚλ³æÓÑÖ§³Ö¡£


ÄÉÃ×ÅÌÏÂÔØµØÖ·£¨ÄÉÃ×Å̺ÃÏñ²»ÊǺÜÎȶ¨£¬ÏÂÔØ²»µ½µÄ³æÓѲ»ÒªËµÁ¬½ÓÎÊÌ⣬ҲÐíÄú»»¸öʱ¼ä¶Î¾Í¿ÉÒÔÁË¡£Èç¹ûÕæµÄ²»ÄÜÏÂÔØÎÒ»á¸üÐÂÁ¬½Ó.Thanks...£©

С¹Ü£¬ÍøËÙÂý£¬´óÎļþ£¬À´Ö®²»Òס£


ÄÉÃ×ÅÌ
http://www.namipan.com/d/Cell%20 ... f7c6064238ef60cc500

´ËÄÉÃ×ÅÌÁ¬½Ó2009Äê1ÔÂ10ÈÕ21£º00ÑéÖ¤£¬Ã»ÓÐʧЧ£¡£¡£¡
ÐÂÔöbrsboxÏÂÔØµØÖ·£º
http://www.brsbox.com/filebox/do ... 30e843450f32c820553


ÍùÍù¾ÍÊÇÕâÑù£¬Óв»µ½10%µÄÈË£¬¼´10¸öÈËÖÐÒ²ÐíÖ»ÓÐÒ»¸ö¸ß̧¹óÊÖ¶Ô·¢×ÊÔ´Õ߸øÓèÁ˹ÄÀø¡£´ó¼Ò¶¼ÕâÑùÏÂÈ¥£¬×ÊÔ´¾ÍºÜÄÑÃâ·ÑÁË¡£¹þ¹þ¡£ä¯ÀÀÁËÒ»ÏÂ×ÊÔ´ÇøµÄ£¬¶¼ÕâÑù¡£Ô¸´ó¼ÒÏÂÔØÇ°Ö§³Ö£¡

[ Last edited by zhwenxing on 2009-1-10 at 20:59 ]
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

ugvgw

Í­³æ (СÓÐÃûÆø)


ллÁËร¬²»ÖªµÀÏÂÁË¿´²»¿´µÃ¶®¿©£¬ºÙºÙ
232Â¥2009-05-15 17:59:32
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 291 ¸ö»Ø´ð

zhwenxing

ľ³æ (ÖøÃûдÊÖ)


²¹È«ÐÅÏ¢£º

¡¶Ï¸°û¡·08Äê11ÔÂ×îÊܹØ×¢µÄʮƪÂÛÎÄ



¡¶Ï¸°û¡·´´¿¯ÓÚ1976Ä꣬ÏÖÒѳÉΪÊÀ½ç×ÔÈ»¿ÆÑ§Ñо¿ÁìÓò×îÖøÃûµÄÆÚ¿¯Ö®Ò»£¬²¢Â½Ðø·¢ÐÐÁËÊ®¼¸ÖÖæ¢Ãÿ¯£¬ÔÚ¸÷×ÔרҵÁìÓòÀï¾ùÕ¼¾ÝמÙ×ãÇáÖØµÄµØÎ»¡£¡¶Ï¸°û¡·ÒÔ·¢±í¾ßÓÐÖØÒªÒâÒåµÄÔ­´´ÐÔ¿ÆÑб¨¸æÎªÖ÷£¬Ðí¶àÉúÃü¿ÆÑ§ÁìÓò×îÖØÒªµÄ·¢ÏÖ¶¼·¢±íÔÚ¡¶Ï¸°û¡·ÉÏ¡£11Ô¡¶Ï¸°û¡·Ç°Ê®ÃûÏÂÔØÂÛÎÄΪ£º

1. An Oncogenomics-Based In Vivo RNAi Screen Identifies Tumor Suppressors in Liver Cancer

ÃÀ¹úÀäȪ¸ÛʵÑéÊÒ5¸ö²»Í¬µÄС×éÁªºÏ½øÐÐÑо¿£¬Ôڸΰ©Öз¢ÏÖÁË13ÖÖеÄÒÖ°©»ùÒò£¬Ñо¿Ð¡×éµÄºÏ×÷ÌṩÁË´ó¹æÄ£¡¢¿ìËÙ¡¢µÍ»¨·ÑµÄÒÅ´«É¸Ñ¡£¬ÔÚǰÆÚʵÑéÖгɹ¦·¢ÏÖ13ÖÖеÄÒÖ°©»ùÒò¡£ÔÚ°©Ö¢ÓÈÆäÊǸΰ©ÖÐÒÖ°©»ùÒòºÜÖØÒª£¬¾­³£»á·¢Ïָΰ©»¼ÕßȱÉÙÁËÒÖ°©»ùÒò¡£

µ±·¢ÉúDNAÍ»±ä¡¢È¾É«ÌåȱʧµÈ¸Ä±äʱÒÖ°©»ùÒò´øÀ´µÄºÃ´¦¿ÉÄܻᶪʧ¡£WiglerС×鼸Äêǰ¿ª·¢³öÒ»ÖÖ¸ßЧ»ùÒò²âÐò¼¼Êõ£¬Ê¹µÃ¼ì²â°©Ï¸°ûÖпÉÄÜ´æÔÚÒÖ°©»ùÒòµÄȱʧȾɫÌ寬¶Î³ÉΪ¿ÉÄÜ¡£

Ñо¿ÈËÔ±¼ì²âÁË100Ãû¸Î°©»¼ÕßµÄȱʧȾɫÌ寬¶Î£¬Æ´³ÉÁËÒ»¶ÎÀíÂÛÉÏ×îÓпÉÄÜ´æÔÚÒÖ°©»ùÒòµÄȾɫÌ寬¶Î¡£Í¨¹ýÓëÕý³£ÈËϸ°ûÖÐȾɫÌåÐòÁеĶԱȣ¬Ñо¿±æÊ¶³öÁËȱʧȾɫÌ寬¶ÎÖеĴóÔ¼300¸ö»ùÒò¡£Ñо¿Ð¡×é²ÉÓÃÁËÐµķ½·¨£¬Í¨¹ýRNA¸ÉÈż¼Êõ£¨RNAi£©À´³ÁÄ¬ÌØ¶¨»ùÒò£¬ÒÔ±æÊ¶»ùÒò¹¦ÄÜ¡£ÕâÒ»·½·¨Óëͨ³£²ÉÓõÄÑо¿Êֶβ»Í¬£¬´ó´óÌá¸ßÁËʱ¼äЧÂÊ¡£

Ñо¿×îºóÈ·ÈÏÁË13ÖÖÐÂÒÖ°©»ùÒò£¬ÆäÖеĴó¶àÊýÈËÃÇ֮ǰ¶¼Ã»ÓÐÒâʶµ½ËüÃǺͰ©Ö¢Óйء£ÂÛÎÄͨѶ×÷Õß¡¢ÀäȪ¸ÛʵÑéÊÒ½ÌÊÚScott W. Lowe±íʾ£º¡°ÕâЩ»ùÒòµÄÐÔÖʲ»ÊǷdz£Ã÷ÏÔ£¬Èç¹ûûÓÐʹÓÃÕâÒ»Ñо¿·½·¨£¬ÎÒÃÇÊÇÎÞ·¨»ñÖªËüÃÇÓë°©Ö¢µÄÁªÏµµÄ¡£ÕâЩ»ùÒòµÄ·¢ÏÖ½«Ôö½øÎÒÃǶ԰©Ö¢µÄÀí½â¡£¡±

2. SIRT1 Redistribution on Chromatin Promotes Genomic Stability but Alters Gene Expression during Aging

Ë¥ÀÏÊÇÈ˺Ͷ¯Îï¶¼ÎÞ·¨±ÜÃâµÄÉúÀí¹ý³Ì£¬ÕæºËϸ°ûÔÚË¥ÀϵĹý³ÌÖлùÒò×é»á±äµÃʧȥÎȶ¨ÐÔ£¬»ùÒò±í´ïÒ²»á»ùÒò×éµÄ²»Îȶ¨ÐÔ¶ø·¢Éú¸Ä±ä¡£Ñо¿·¢ÏÖ£¬½Íĸϸ°ûÖеÄ×éµ°°×ÍÑÒÒõ£»ùøSir2¾ßÓгÁĬת¼×ÓºÍÎȶ¨Öظ´DNAµÄ¹¦Ð§£¬µ«ÊÇ£¬µ±Ï¸°û¿ªÊ¼ÀÏ»¯»òÊÇDNA¶ÏÁÑÇé¿ö·¢ÉúµÄʱºò£¬Sir¸´ºÏÎï»áʧȥԭÀ´µÄ¹¦ÄÜ£¬±äµÃ²»¾ßÓгÁĬ»ùÒòµÄÄÜÁ¦£¬²¢×îÖÕµ¼Ö½Íĸʧȥ×ÔÎÒÔöÖ³µÄÄÜÁ¦£¬ÕâÊǽÍĸÀÏ»¯¹ý³ÌÖаéËæ·¢ÉúµÄµäÐÍÌØÕ÷¡£

ΪÁ˽ⲸÈ鶯ÎïÊÇ·ñ¾ßÓÐÏàËÆµÄÇé¿ö£¬Ñо¿ÕßÓÃСÊóÅßÌ¥¸Éϸ°ûÀ´½øÐÐÊÔÑ飬½á¹û·¢ÏÖSIRT1µÄ¹¦ÄÜÓë½ÍĸµÄ Sir2ÏàËÆ£¬SIRT1¾ßÓÐÒÖÖÆÖØ¸´DNAƬ¶Î¸÷ÖÖ»ùÒò±í´ïµÄ¹¦ÄÜ¡£µ±DNA·¢Éú¶ÏÁѵÄÇé¿öʱ£¬SIRT1¾Í»á´Ó»ùÒò×éת×ù×ÓÉϵôÂ䣬²¢ÖØÐ¶¨Î»´Ù½ø DNAÐÞ¸´£¬¸Ä±äת¼¹ý³Ì£¬ÕâÒ»Çé¿öÔÚÀÏ»¯µÄϸ°ûÖÐͬÑù»á³öÏÖ¡£Èç¹ûÔö¼ÓSIRT1µÄ±í´ïÁ¿¿ÉÓÐЧ±£»¤»ùÒò×éÎȶ¨ÐÔÔâÆÆ»µµÄϸ°ûά³Ö»îÐÔ£¬ÒÖÖÆÀÏ»¯´øÀ´µÄ»ùÒò×éת¼±ä»¯¡£

ËùÒÔ˵£¬DNAÔìµ½ÆÆ»µ¿ÉÓÕµ¼SIRT1ÖØÐ·ÖÅ䣬²¢ËæÖ®¸Ä±ä»ùÒò×éµÄת¼Çé¿ö£¬¸Ä±äµ°°×µÄ±í´ïÇé¿ö£¬ÕâÒ»»úÖÆ¿ÉÄÜÊÇÕæºËϸ°ûÔÚÀÏ»¯¹ý³ÌÖÐÒ»¸ö±£ÊصĻúÖÆ¡£

3. Myosin Vb Mobilizes Recycling Endosomes and AMPA Receptors for Postsynaptic Plasticity

ÄÔÈçºÎÐγÉÒ»´Î¼ÇÒ䣿ͨ³££¬ÎÒÃǵľ­ÀúºÍÏ໥×÷ÓûáÒÔijÖÖ·½Ê½ÔÚ´óÄÔÖÐÁôÏÂÀÓÓ¡£¬È»¶øÉñ¾­Ï¸°û¾¿¾¹ÊÇÈçºÎ¸Ä±äËüÃǵÄÁ¬½Ó´Ó¶øÐγɼÇÒ䣬ȴһֱÊǸöδ½âÖ®ÃÕ¡£Èç½ñ£¬¿ÆÑ§¼Ò±íʾ£¬ËûÃÇÕÒµ½Á˽«¾­ÀúÓëÈÏÖªÁªÏµÆðÀ´µÄ·Ö×Ó»úÖÆ£¬¶øÕâÒ»ÇÐËÆºõÈ«²¿Òª¹é¹¦ÓÚһ̨΢СµÄ·Ö×Ó·¢¶¯»ú¡£

¿ÆÑ§¼ÒÏàÐÅ£¬¼ÇÒäµÄ´æ´¢ÓëÒ»¸öÃûΪ³¤Ê±³ÌÔöÇ¿£¨LTP£©µÄ¹ý³ÌÓйأ¬¸Ã¹ý³ÌÇ¿»¯ÁËÉñ¾­Ï¸°û¶ÔÖ®¼äµÄÁªÏµ¡£Éñ¾­Ï¸°ûͨ¹ýÊÍ·ÅÉñ¾­´«µÝËØ¡ª¡ªÓÃÓڴ̼¤ÖÜΧ¡°ÁÚ¾Ó¡±µÄÊÜÌ塪¡ªÀ´½øÐн»Á÷£¬¶øLTPÄܹ»´¥·¢¸ü¶àµÄÊÜÌå¾Û¼¯ÔÚ½ÓÊÕϸ°ûµÄϸ°ûĤÉÏ£¬´Ó¶øÊ¹Æä¶ÔÓÚµ½À´µÄÐÅÏ¢¸üΪÃô¸Ð¡£

֮ǰµÄÑо¿±íÃ÷£¬¼¡¶¯µ°°×ºÍ¼¡Çòµ°°×¡ª¡ªÔÚ¼¡ÈâÊÕËõÖаçÑÝÖØÒª½ÇÉ«µÄÁ½ÖÖµ°°×ÖÊ¡ª¡ªÔÚÉñ¾­Ï¸°ûµÄÊÜÌå»ý¾Û¹ý³ÌÖÐÆðµ½Á˹ؼü×÷Óá£ÎªÁËÑо¿ÕâÖÖ¿ÉÄÜÐÔ£¬ÃÀ¹ú±±¿¨ÂÞÀ³ÄÉÖÝ´ïÀÕÄ·Êжſ˴óѧҽѧÖÐÐĵÄÉñ¾­ÉúÎïѧ¼ÒMichael EhlersºÍËûµÄͬÊ£¬ÀûÓö¨Ê±³ÉÏñºÍÉúÎﻯѧ·½·¨£¬¶ÔСÊóµÄ´óÄÔÇÐÆ¬½øÐÐÁËÑо¿¡£ÕâЩÊÔÑéÏÔʾ£¬Ò»¸öÒýÈëµÄÐźÅÄܹ»´¥·¢´óÁ¿µÄ¸Æ½øÈëÒ»¸öÉñ¾­Ï¸°û¡£ÕâЩ¸Æ»á¼¤»îÒ»ÖÖ¼¡Çòµ°°×¡ª¡ª¼¡Çòµ°°×Vb£¬´Ó¶ø´ÙʹËü»ñµÃ´¢´æÔÚϸ°ûÉî´¦µÄÊÜÌå°ü£¬²¢½«ÕâЩÊÜÌå°ü´øµ½Éñ¾­Ï¸°ûµÄÐźÅλµã£¬ÔÚÕâÀÊÜÌåÄܹ»½ÓÊÕÉñ¾­´«µÝËØ£¬²¢²ÎÓëLTP¹ý³Ì¡£

Ϊ֤ʵ¼¡Çòµ°°×VbµÄÈ·ÊÇÈÃÈÏÖª¹ý³Ì±äΪ¿ÉÄܵķ¢¶¯»ú£¬EhlersºÍËûµÄͬÊÂÀûÓû¯Ñ§·½·¨ÒÖÖÆÉñ¾­Ï¸°ûÖеļ¡Çòµ°°×Vb£¬ÕâЩϸ°ûÓÚÊDZãÎÞ·¨²úÉúLTP¡£Ñо¿ÈËÔ±ÔÚ¡¶Ï¸°û¡·ÔÓÖ¾Éϱ¨¸æÁËÕâÒ»Ñо¿³É¹û¡£EhlersÖ¸³ö£º¡°¶ÔÓÚÒ»¸öÂí´ï·Ö×Ó¾¹È»Äܹ»½âÊÍ´ó¶àÊýµÄĤ´«Êä¹ý³Ì£¬ÎÒÃǸе½·Ç³£¾ªÑÈ¡£ÊÂʵÉÏ£¬ËüºÜ¿ÉÄܾÍÊÇÐγɼÇÒäµÄ¡®·¢¶¯»ú¡¯¡£¡±

4. Telomerase Reverse Transcriptase Delays Aging in Cancer-Resistant Mice

¶ËÁ£Äæ×ªÂ¼Ã¸ÑÓ»º°©Ö¢µÖ¿¹ÐÔÀÏÊóµÄË¥ÀϽø³Ì

¶ËÁ£Ã¸Í¨¹ýÑÓ³¤È¾É«Ìå¶ËλÉϵÄ×ÅË¿µã£¬Îª´ó¶àÊýÈËÀàϸ°ûÌṩÁËÎÞÏÞµÄÔöÖ³ÄÜÁ¦£¬·ñÔòȾɫÌ彫Êܵ½Ëðʧ²¢×îÖÕ½µµÍÔöÖ³ÄÜÁ¦¡£È»¶øÈËÃǶԶËÁ£Ã¸ÔÚÓлúÌåÀÏ»¯Ê±ËùÆðµÄ×÷ÓÃÒ»Ö±²»ÉõÁ˽⣬ÆäÖÐÒ»²¿·ÖÔ­Òò¾ÍÊǶËÁ£Ã¸Äܹ»´Ùʹ°©Ö¢µÄ·¢Éú¡£ÎªÁËÈÆ¿ªÕâ¸öÎÊÌ⣬ÎÄÕÂ×÷ÕßÔÚͨ¹ý¼ÓÇ¿ÒÖÖÆ°©Ö¢Òò×Óp53¡¢p16ºÍ p19ARF±í´ïËù½¨Á¢µÄ¿¹°©Ð¡ÊóÄ£ÐÍÖУ¬¶Ô¶ËÁ£Ã¸µÄ×é·ÖÖ®Ò»¶ËÁ£Äæ×ªÂ¼Ã¸(TERT)µÄ±í´ï·ÖÎö¡£ÔÚÕâÖÖ±³¾°Ï£¬TERTµÄ¹ýÁ¿±í´ïÄܹ»¸ÄÉÆÓÈÆäÊÇÆ¤·ôºÍС³¦ÉÏÆ¤µÄ·ÀÓùÄÜÁ¦£¬²¢ÄܲúÉúÒ»ÖÖÍÆ³Ùϸ°ûϵͳÀÏ»¯µÄ×÷Óá£ÕâЩÑо¿½á¹û±íÃ÷ÔÚ²¸È鶯ÎïÓлúÌå±³¾°Ï£¬¶ËÁ£Äæ×ªÂ¼Ã¸Äܹ»²úÉú¿¹»úÌåÀÏ»¯µÄ×÷Óá£

5. N-acylphosphatidylethanolamine, a Gut- Derived Circulating Factor Induced by Fat Ingestion, Inhibits Food Intake

N-õ£»ùÁ×Ö¬õ£ÒÒ´¼°·£¨N-acylphosphatidylethanolamines £¬NAPEs£©ÊÇÔÚѪ֬Öк¬Á¿Ïà¶Ô½Ï·á¸»µÄÎïÖÊ£¬µ«ÊÇÒ»Ö±ÒÔÀ´¿ÆÑ§¼ÒÃǶ¼²»Á˽âËüµÄÉúÀí×÷Óá£

ÔÚ±¾Ñо¿ÖУ¬¿ÆÑ§¼ÒÃÇ·¢ÏÖNAPEsÆäʵÊÇС³¦ÔÚÏû»¯Ö¬·¾µÄ¹ý³ÌÖзÖÃÚµÄÒ»ÖÖ»îÐÔÎïÖÊ£¬ÔÚÉúÀí¼ÁÁ¿ÏÂNAPEs¾ßÓнµµÍʳÓû£¬ÒÖÖÆ½øÊ³µÄ¹¦ÄÜ£¬²¢ÇÒͨ¹ý¶¯ÎïʵÑé֤ʵ²»»á²úÉúÌõ¼þÐÔζ¾õÑá¶ñ£¨Ñáʳ£©Çé¿ö¡£

²¢ÇÒÑо¿ÕßÓÃC14Í¬Î»ËØ±ê¼ÇNAPEs£¬·¢ÏÖNAPEsÔ½¹ýѪÄÔÆÁÕϽøÈë´óÄÔºó£¬ÔÚÏÂÇðÄÔ²¿¼¯ÖÐÆðÀ´£¬ÏÂÇðÄÔ²¿µÄNAPEsŨ¶ÈÉý¸ß£¬´Ì¼¤Éñ¾­ÒÖÖÆ½øÊ³¡£ÕâÒ»½á¹û±íÃ÷£¬NAPEs¿ÉÖ±½Ó×÷ÓÃÓÚÖÐÊàÉñ¾­ÏµÍ³ÒÖÖÆ½øÊ³¡£

Ñо¿Õß·¢ÏÖ£¬NAPEs¾ßÓг¤Ð§ÒÖÖÆ½øÊ³ºÍÌåÖØÔö¼ÓµÄ¹¦ÄÜ¡£ÕâÒâζ×ÅNAPEsºÍËüµÄͬϵÎï¿ÉÄܳÉΪ·ÊÅÖÖÎÁƵÄаÐλ¡£

6. Hematopoietic Stem Cells Reversibly Switch from Dormancy to Self-Renewal during Homeostasis and Repair

¹ÇËèÔìѪ¸Éϸ°ûÊÇÉúÎïÌåÄÚά³ÖѪϸ°û¸üеÄÖØÒªÏ¸°ûϵ¡£¾¡¹Ü£¬¹ÇËèÔìѪ¸Éϸ°û·Ö»¯µÄƵÂʺܵͣ¬µ«ÊÇ¿ÆÑ§¼ÒÃÇÈÏΪ¹ÇËèÔìѪ¸Éϸ°û¿â³£ÊýÐÇÆÚ¸üÐÂÒ»´Î£¬Õâ±íÃ÷¹ÇËèÔìѪ¸Éϸ°ûºÜÓйæÂɵؽøÈë»òÊÇÍ˳öϸ°ûÖÜÆÚ¡£

ÔÚ±¾Ñо¿ÖУ¬¿ÆÑ§¼ÒʹÓÃÁ÷ʽϸ°û¼ÆÊý¼¼Êõ£¨´øÓÐBrdU and histone H2B-GFP±êÇ©£©¼ø¶¨³öСÊóµÄÐÝÃß¹ÇËèÔìѪ¸Éϸ°û£¨dormant mouse bone marrow hematopoietic stem cells£¬ d-HSC£©£¬±íÏÖΪlin−Sca1+cKit+CD150+CD48−CD34− ¡£

ÓüÆËã»úÄ£ÐÍÔ¤²âµÃ³ö½áÂÛ£¬ÕâЩÐÝÃߵĹÇËèÔìѪ¸Éϸ°ûÿ145Ìì×ÔÎÒ¸üÐÂÒ»´Î£¬ÔÚËüÕû¸öÉúÃüÖÜÆÚÀï¹²¸üÐÂ5´Î¡£ÐÝÃߵĹÇËèÔìѪ¸Éϸ°û¾ßÓжàÖÖ×ÔÎÒ¸üеĻîÐÔ¡£ÔÚÄÚ»·¾³Î¬³ÖÎȶ¨µÄÇé¿öÏ£¬ÐÝÃߵĹÇËèÔìѪ¸Éϸ°û¼ÌÐø±£³ÖÐÝÃß״̬£¬µ±¹ÇËèÊܵ½ËðÉË»òÊÇÔÚG-CSFµÄ´Ì¼¤Ï£¬¹ÇËèÔìѪ¸Éϸ°ûÓÖ»Ö¸´×ÔÎÒ¸üеĻîÁ¦¡£·Ö»¯³öеÄѪҺϸ°ûά³ÖÄÚ»·¾³µÄÎÈ̬£¬»îÔ¾·Ö»¯ºóµÄÔìѪ¸Éϸ°ûÔÚÉúÃüÖÜÆÚÄÚÔڴ˻ع鵽ÐÝÃß״̬¡£

ÕâЩÑо¿½á¹û±íÃ÷£¬¹ÇËèÔìѪ¸Éϸ°ûÒ»°ã´¦ÓÚÐÝÃß״̬£¬Ö»ÓгöÏÖÔìѪѹÁ¦µÄʱºò²Å»á±»¼¤»î£¬²úÉú×ÔÎÒ¸üеÄÄÜÁ¦¡£

7. H2AZ Is Enriched at Polycomb Complex Target Genes in ES Cells and Is Necessary for Lineage Commitment

ÉúÃüÆðÔ´ÓÚÅßÌ¥¸Éϸ°û£¬ÉúÎïµÄ¶àÑùÐÔÀ´×ÔÓÚ¸Éϸ°ûµÄ¶àÄÜÐÔ¡£ÅßÌ¥¸Éϸ°ûµÄ·¢ÓýÊÇÒ»¸ö¸´ÔÓµÄÉúÀí¹ý³Ì£¬ÔÚÅßÌ¥¸Éϸ°ûµÄ·Ö»¯·¢Óý¹ý³ÌÖÐÊܶà¸ö»ùÒòµÄµ÷¿Ø£¬ÕâÒ»¹ý³ÌÒ²Ò»Ö±ÊÇ¿ÆÑ§¼ÒÃÇØ½´ýÁ˽âµÄÉñÃØ¹ý³Ì¡£ÓÈÆäÊǶÔÅßÌ¥¸Éϸ°ûµÄÁ˽âÓÐÖúÓÚÁ˽âÈËÀ༲²¡µÄ·¢Éú·¢Õ¹»úÖÆ¡£Òò´Ë£¬¸Éϸ°û·¢ÓýÓë»ùÒòµ÷½ÚµÄ¹ØÏµ¾Í³ÉΪÑо¿Õß²»Ð¸Å¬Á¦µÄ·½Ïò¡£

Ñо¿·¢ÏÖ£¬±äÒìµÄ×éµ°°×H2AZÔÚȾɫÖʹ¦Äܵķ¢Óý¹ý³ÌÖÐÊÇÒ»¸ö¹Ø¼üµÄµ÷¿ØÒò×Ó£¬¶Ô»ùÒò±í´ïµÈ¹¦ÄÜÆäÖØÒªµÄ×÷Ó㬵«ÊÇÈËÃÇȴһֱûÓнҿªH2AZ×éµ°°×µÄÉñÃØÃæÉ´£¬¾¿¾¹ËüÊÇÈçºÎ·¢»Ó×÷Óã¬ÈËÃÇÒ»ÎÞËùÖª¡£

ÔÚ±¾ÎÄÕÂÖУ¬ÂéÊ¡Àí¹¤ºÍ¹þ·ð°×Í·Ñо¿ËùµÄ¿ÆÑ§¼Ò½«´Ó»ùÒò×éѧµÄˮƽ·ÖÎöH2AZ£¬ÐµÄÑо¿½á¹û±íÃ÷H2AZµÄ×÷ÓÃģʽÓëPcG£¨Polycomb group£©µ°°×Suz12¾ªÈ˵ÄÏàËÆ£¬ËüÃÇÊÇÄ³Ð©ÖØÒªµÄ»ùÒòµÄÆô¶¯×Óµ°°×¡£

8. The Growth Factor Environment Defines Distinct Pluripotent Ground States in Novel Blastocyst-Derived Stem Cells

ϸ°û¾ßÓжàÄÜÐÔ£¬ÕâÊÇÒ»ÖÖά³Öϸ°û×ÔÎÒ¸üÐÂÒÔ¼°²úÉúÈýÅß²ãÑÜÉú×éÖ¯µÄÄÜÁ¦¡£³¤¾ÃÒÔÀ´¿ÆÑ§¼ÒÃÇÒ»Ö±ÈÏΪ£¬¸Éϸ°û¶àÄÜÐÔÊÇÒ»ÖÖµ¥Ò»µÄ¸ß½×»ù̬£¬²¢ÇÒËæ×Åϸ°û·Ö»¯µÄ¿ªÊ¼¶øÖð²½É¥Ê§¡£¶øÔÚ2008Äê10ÔÂ31ÈÕ³ö°æµÄ¡¶Ï¸°û¡·ÉÏ£¬À´×ÔÃÀ¹úÂéÊ¡×ÛºÏÒ½ÔºµÄYu-Fen ChouµÈ¿ÆÑ§¼ÒÈÏΪ£¬ÊÂʵÉÏ´æÔÚ¶à¸öÕâÑùµÄ»ù̬£¬Ã¿Ò»¸ö»ù̬¶¼¾ßÓÐ×ÔÉí¶ÀÌØµÄ·Ö×ÓºÍÉúÎïÑ§ÌØÐÔ¡£

Ñо¿Ð¡×éÖ¤Ã÷Á˸Éϸ°ûÄÜ´ÓÒ»¸ö̬ת»¯µ½ÁíÒ»¸ö̬£¬¶øÒÔÉϹý³ÌºÜ´ó³Ì¶ÈÉÏÈ¡¾öÓÚϸ°ûÉú³¤Òò×Ó΢»·¾³¡£¶àÄܸÉϸ°ûϵ£¨pluripotent stem cell line£©ÄÜÓÉÄÒÅß²úÉú£¬ÕâÒ»²¿·Ö×îÖյõ½ÅßÌ¥¸Éϸ°ûϵ£¨embryonic stem cell line£¬ES cell line£©£¬¶øÁíÒ»²¿·Ö¶àÄܸÉϸ°ûÀ´×ÔÓÚÉÏÅ߲㣬Õⲿ·Ö×îÖյõ½ÉÏÅß²ã¸Éϸ°ûϵ£¨epiblast stem cell line£¬EpiSCs line£©¡£¶øESϸ°ûÒÔ¼°EpiSCsϸ°ûÔÚ½áºÏά³ÖÆä¶àÄÜ״̬µÄÉú³¤Òò×Óʱ±íÏÖ³ö¼«´óµÄ²îÒì¡£ÕâÁ½ÖÖ¸Éϸ°ûÖÖÀàµÄ·Ö×ÓÒÔ¼°¹¦ÄÜÉϵIJî±ðÖ¤Ã÷£¬×éÖ¯À´Ô´ºÍÉú³¤Òò×Ó»·¾³»òÐí¶ÔÓÚ¾ö¶¨¸Éϸ°ûÀàÐͷdz£ÖØÒª¡£

9. Real-Time Redox Measurements during Endoplasmic Reticulum Stress Reveal Interlinked Protein Folding Functions

ÄÚÖÊÍøÓ°Ïìµ°°×ÕÛµþ¹¦ÄܵÄʵʱÑõ»¯»¹Ô­²â¶¨

¶ÔÄÚÖÊÍø£¨ER£©µ°°×ÖÊÕÛµþµÄÆÆ»µ£¬Äܵ¼ÖÂδÕÛµþµ°°×µÄ¶Ñ»ý£¬´Ó¶øÒý·¢Æä²úÉúÓ¦´ð(UPR)¡£Ïà·´£¬UPRµÄ¼õÉÙ¿ÉʹERδÕÛµþµ°°×½Ó½ü¸º·´À¡»ØÂ·¡£µ«ÊÇ£¬ÓÉÓÚÎÞ·¨²âÁ¿µ½ÌåÄÚδÕÛµþµ°°×µÄŨ¶È£¬ËùÒÔÎÞÂÛUPRÈçºÎÔË×÷£¬¶¼±»ÈÏΪÊÇ¡°ERµÄ¹¦ÀÍ¡±¡£ÒòΪERÑõ»¯»¹Ô­µçλÓëÑõ»¯µÄµ°°×ÕÛµþ×îÏàÅ䣬ËùÒÔÑо¿ÈËÔ±ÍÆ¶Ïͨ¹ýÑõ»¯»¹Ô­Á¿µÄ¼ì²â£¬Äܹ»µÃ֪δÕÛµþµ°°×µÄ»ýÀÛÁ¿¡£ÎªÁËÑéÖ¤ÕâÒ»Ïë·¨£¬Ñо¿ÈËÔ±ÀûÓÃÓ«¹âµ°°×¼¼Êõ£¬¶ÔERÑõ»¯»¹Ô­×´Ì¬ºÍµ¥Ò»Ï¸°ûÖÐERµÄ»î¶¯½øÐÐÁ˶¯Ì¬¼à²â¡£Í¨¹ýÕâЩÊֶΣ¬×¨¼ÒÃÇ·¢ÏÖÁ˲»Í¬µÄѹÁ¦ÒòËØ£¬°üÀ¨ÊµÑéÐԵĺÍÉúÀíѧÉϵģ¬ÕâЩÒòËØÔÚµ±UPRÇ¿ÖÆÄÚÆ½ºâ¿ØÖÆÊ§Ð§Ê±£¬ÄÜʹERµ°°×±»Ñõ»¯¡£Í¨¹ý»ùÒò·ÖÎö£¬Ñо¿ÈËÔ±½ÒʾÁ˵ȻùÒòϸ°ûȺÖÐÑõ»¯»¹Ô­µÄÒìÖÊÐÔ£¬²¢ÏÔʾÁËERµ°°×ÕÛµþ¡¢ÐÞÊκÍÖÊÁ¿¿ØÖÆÏµÍ³¹¦ÄܼäµÄÁªÏµ¡£

10. Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum

Lrp5Ó°Ïì¹ÇÖʵÄ;¾¶

Lrp5»ùÒò±í´ïµÄȱʧ»òÔö¼ÓÓ°Ïì׏Ç÷ÀµÄÐγɣ¬Äܹ»µ¼Ö¹ÇÖÊÊèËɺ͹ÇÖÊÔöÉú¡£ËäÈ»Lrp5±»ÊÓΪWntÐźÅÊÜÌ壬µ«ÊǦÂ-µ°°×µÄ³É¹Çϸ°ûÌØ¶¨·ÖÁѲ»»áÓ°Ïì¹Ç÷ÀµÄÐγɡ£Ïà·´µÄ£¬×÷ÕßΪÎÒÃÇչʾÁË£¬Lrp5Äܹ»ÒÖÖÆTph1µÄ±í´ï¡£Tph1ÊÇÊ®¶þÖ¸³¦Êȸõϸ°ûµÄÏÞËÙø¡£Òò´Ë£¬½µµÍѪҺôÇÉ«°·Ë®Æ½Äܹ»»Ø¸´Lrp5ȱÏÝСÊóµÄ¹Ç÷ÀÐγɺÍÖÊÁ¿¡£´ËÍ⣬³¦Lrp5µÄÌØ¶¨¼¤»î»òTph1µÄÃð»î£¬Äܹ»Ôö¼Ó¹ÇÖÊÃܶȣ¬·±Ö³Âѳ²ÇгýºóÒý·¢µÄ¹ÇÖʶªÊ§¡£ÑªÇåËØÍ¨¹ýHtr1bÊÜÌåºÍÁ×Ëữ×÷ÓÃÒÖÖÆ³É¹Çϸ°ûµÄÀ©É¢¡£´ËÏîÑо¿À©Õ¹ÁËÎÒÃǶԹÇÖÊÖØ½¨µÄÁ˽⣬ÓÐÖúÓÚ¶ÔÏà¹ØÒ½ÁÆ·½·¨µÄÑо¿¡££¨À´Ô´£ºÉúÎïͨ£©
2Â¥2009-01-09 19:03:56
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

zhwenxing

ľ³æ (ÖøÃûдÊÖ)



httpÏÂÔØ²»¿ÉÒÔµÄÇ밲װʹÓà   ÄÉÃ×»úÆ÷ÈË  ¿Í»§¶Ë³ÌÐò ÏÂÔØ£¡
3Â¥2009-01-09 19:05:46
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

haiven

¾èÖú¹ó±ö (ÖøÃûдÊÖ)


¡ï¡ï¡ï ÈýÐǼ¶,Ö§³Ö¹ÄÀø

лÁË¡£¡£¡£½ñÌì¿´µ½²ÅÄÜÏ£¡£¡
6Â¥2009-01-10 08:59:28
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
¡î ÎÞÐǼ¶ ¡ï Ò»ÐǼ¶ ¡ï¡ï¡ï ÈýÐǼ¶ ¡ï¡ï¡ï¡ï¡ï ÎåÐǼ¶
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] 0805 316Çóµ÷¼Á +6 ´óÑ©Éî²Ø 2026-03-18 6/300 2026-03-24 22:13 by peike
[¿¼ÑÐ] 0703»¯Ñ§µ÷¼Á£¬Çóµ¼Ê¦ÊÕ +7 ÌìÌìºÃÔËÀ´Éϰ¶° 2026-03-24 7/350 2026-03-24 20:26 by peike
[¿¼ÑÐ] 307Çóµ÷¼Á +5 ³¬¼¶ÒÁ°º´óÍõ 2026-03-24 5/250 2026-03-24 15:46 by ÐÇ¿ÕÐÇÔÂ
[¿¼ÑÐ] 277·ÖÇóµ÷¼Á£¬¿çµ÷²ÄÁÏ +3 ¿¼Ñе÷¼Álxh 2026-03-24 3/150 2026-03-24 13:52 by JourneyLucky
[¿¼ÑÐ] 081700 µ÷¼Á 267·Ö +9 ÃÔÈ˵Ĺþ¹þ 2026-03-23 9/450 2026-03-24 11:58 by 544594351
[¿¼ÑÐ] Çó²ÄÁÏ£¬»·¾³×¨Òµµ÷¼Á +3 18567500178 2026-03-18 3/150 2026-03-23 23:50 by ÈÈÇéɳĮ
[¿¼ÑÐ] Ò»Ö¾Ô¸ÉÂʦ´óÉúÎïѧ071000£¬298·Ö£¬Çóµ÷¼Á +3 SYA£¡ 2026-03-23 3/150 2026-03-23 19:09 by macy2011
[¿¼ÑÐ] ±±¿Æ281ѧ˶²ÄÁÏÇóµ÷¼Á +8 tcxiaoxx 2026-03-20 9/450 2026-03-23 12:16 by tcxiaoxx
[¿¼ÑÐ] 298Çóµ÷¼Á +8 Éϰ¶6666@ 2026-03-20 8/400 2026-03-23 11:02 by laoshidan
[¿¼ÑÐ] 324Çóµ÷¼Á +6 luckyѽѽѽѼ 2026-03-20 6/300 2026-03-22 16:01 by ColorlessPI
[¿¼ÑÐ] Ò»Ö¾Ô¸ Î÷±±´óѧ £¬070300»¯Ñ§Ñ§Ë¶£¬×Ü·Ö287£¬Ë«·ÇÒ»±¾£¬Çóµ÷¼Á¡£ +3 ³¿»èÏßÓëÐǺ£ 2026-03-20 3/150 2026-03-22 16:00 by ColorlessPI
[¿¼ÑÐ] 298Çóµ÷¼ÁÒ»Ö¾Ô¸211 +3 Éϰ¶6666@ 2026-03-20 3/150 2026-03-22 15:50 by ColorlessPI
[¿¼ÑÐ] 085600²ÄÁÏÓ뻯¹¤306 +4 z1z2z3879 2026-03-21 4/200 2026-03-21 23:44 by ms629
[¿¼ÑÐ] 297Çóµ÷¼Á +11 Ï·¾«µ¤µ¤µ¤ 2026-03-17 12/600 2026-03-21 17:47 by ColorlessPI
[¿¼ÑÐ] Ò»Ö¾Ô¸ÖØÇì´óѧ085700×ÊÔ´Óë»·¾³×Ü·Ö308Çóµ÷¼Á +7 īīĮ 2026-03-20 7/350 2026-03-21 16:36 by barlinike
[¿¼ÑÐ] 324·Ö 085600²ÄÁÏ»¯¹¤Çóµ÷¼Á +4 llllkkkhh 2026-03-18 4/200 2026-03-21 01:24 by JourneyLucky
[¿¼ÑÐ] Ò»Ö¾Ô¸»ªÖпƼ¼´óѧ£¬080502£¬354·ÖÇóµ÷¼Á +5 ÊØºòϦÑôCF 2026-03-18 5/250 2026-03-21 01:06 by JourneyLucky
[¿¼ÑÐ] 274Çóµ÷¼Á +10 S.H1 2026-03-18 10/500 2026-03-20 23:51 by JourneyLucky
[¿¼ÑÐ] Ò»Ö¾Ô¸ ÄϾ©º½¿Õº½Ìì´óѧ´óѧ £¬080500²ÄÁÏ¿ÆÑ§Ó빤³Ìѧ˶ +5 @taotao 2026-03-20 5/250 2026-03-20 20:16 by JourneyLucky
[¿¼ÑÐ] Ò»Ö¾Ô¸¸£´ó288Óлú»¯Ñ§£¬Çóµ÷¼Á +3 Сľ³æ200408204 2026-03-18 3/150 2026-03-19 13:31 by houyaoxu
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û